Shares of Avanos Medical Inc (NYSE:AVNS) have received a consensus rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $51.25.
A number of research firms recently issued reports on AVNS. ValuEngine raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Zacks Investment Research downgraded shares of Avanos Medical from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Raymond James lowered their price target on shares of Avanos Medical from $57.00 to $48.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley set a $47.00 price target on shares of Avanos Medical and gave the company a “sell” rating in a report on Wednesday, May 8th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Avanos Medical and gave the company a “buy” rating in a report on Wednesday, August 7th.
Shares of AVNS traded up $0.42 on Friday, reaching $36.55. The company’s stock had a trading volume of 226,200 shares, compared to its average volume of 340,787. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.06 and a quick ratio of 2.35. The stock has a market capitalization of $1.72 billion, a P/E ratio of 44.57 and a beta of 1.46. The stock’s 50 day simple moving average is $40.87 and its two-hundred day simple moving average is $43.00. Avanos Medical has a 12-month low of $35.21 and a 12-month high of $72.96.
In other news, CEO Joseph Fralin Woody purchased 3,500 shares of the stock in a transaction on Thursday, May 30th. The shares were acquired at an average price of $39.95 per share, with a total value of $139,825.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.57% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of AVNS. Norges Bank bought a new stake in shares of Avanos Medical during the fourth quarter valued at approximately $33,253,000. RGM Capital LLC raised its position in shares of Avanos Medical by 1,659.3% during the second quarter. RGM Capital LLC now owns 751,523 shares of the company’s stock valued at $32,774,000 after buying an additional 708,806 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Avanos Medical by 31.3% during the first quarter. Victory Capital Management Inc. now owns 2,196,725 shares of the company’s stock valued at $93,756,000 after buying an additional 523,550 shares during the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of Avanos Medical during the first quarter valued at approximately $16,219,000. Finally, Champlain Investment Partners LLC raised its position in shares of Avanos Medical by 14.5% during the first quarter. Champlain Investment Partners LLC now owns 2,401,987 shares of the company’s stock valued at $102,517,000 after buying an additional 304,015 shares during the last quarter. 92.24% of the stock is currently owned by institutional investors and hedge funds.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Further Reading: How mutual funds make money
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.